CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This large study is investigating new ways to treat advanced bowel cancer, specifically in patients whose cancer has certain genetic features called MSI-H or dMMR. Researchers are comparing two new drug combinations, one with Nivolumab alone and another with Nivolumab plus Ipilimumab, against the chemotherapy treatments doctors usually choose. The main goal is to find out which treatment is most effective at stopping the cancer from growing or getting worse. It also checks how long people live and how many see their tumours shrink. The study aims to confirm if these newer drug combinations offer a better option for patients.
At a glance
What is this study about?
This study is a clinical trial, which means it's a research study involving people. It's looking at new treatments for a type of bowel cancer that has spread to other parts of the body, known as metastatic colorectal cancer. Specifically, it focuses on cancers with particular changes in their genes, which doctors call Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR). These genetic changes can sometimes mean that certain newer drugs, like immunotherapies, might work better.
The main aim of this study is to compare the effectiveness of different medications. Some patients will receive Nivolumab by itself, while others will get Nivolumab alongside another drug called Ipilimumab. Both Nivolumab and Ipilimumab are types of immunotherapy, which work by helping your own immune system fight the cancer. The study will compare these new approaches against the standard chemotherapy treatments that doctors currently use for this type of cancer. This will help understand if the investigational drugs are better at controlling the cancer's growth.
Researchers will closely watch how long patients live and how long their cancer stays under control without getting worse. They'll also look at whether tumours shrink in size. This is a "Phase 3" trial, which means it's a large and important step to confirm if a new treatment is truly safe and effective before it can become widely available. The ultimate goal is to find better treatment options for people living with advanced bowel cancer that has these specific genetic features.
Key takeaways
- This study explores new treatments for advanced bowel cancer with specific genetic markers.
- It compares new immunology drugs (Nivolumab, Ipilimumab) with standard chemotherapy.
- The main aim is to see which treatment best stops cancer growth.
- Patients receive treatment via infusion and have regular check-ups and scans.
- Being in the study means getting new treatments and close medical attention.
- You can stop participating at any time.
Who may be eligible?
To be considered for this study, you would need to be at least 18 years old. The study is open to both men and women.
The most important health requirement for this study is that you must have bowel cancer that has spread to other parts of your body. Your cancer also needs to have specific genetic features, described by doctors as Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR). These specific features are usually found through special tests on your cancer tissue.
There might be other health conditions or previous treatments that could affect whether you can join, as these studies need to ensure patient safety and that the results are clear. Your doctor would discuss all the specific criteria with you in detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years of age or older?
- Do you have bowel cancer that has spread to other parts of your body?
- Has your doctor told you your cancer has MSI-H or dMMR genetic features?
- Are you able to attend regular hospital appointments for treatment and tests?
What does participation involve?
If you decide to take part in this study, you would be randomly assigned to one of several treatment groups. This is a bit like drawing straws, ensuring fairness. You could receive either Nivolumab alone, Nivolumab combined with Ipilimumab, or a chemotherapy treatment decided by your doctor from a selection of commonly used drugs. All these drugs are given as an infusion, meaning they are delivered directly into your bloodstream, usually through a drip.
Throughout the study, you would have regular hospital visits for your treatments and check-ups. These visits would include blood tests, physical examinations, and scans (like CT or MRI scans) to see how your cancer is responding and to monitor for any side effects. The exact number of visits and the total duration in the study would depend on your treatment plan and how your body responds to the medication. You would continue treatment as long as it is helping you and the side effects are manageable, or until the study requires a stop. There would also be a follow-up period after your treatment finishes to monitor your long-term health.
Potential risks and benefits
Locations (12)
- —UnverifiedAustria
- —UnverifiedItaly
- —UnverifiedSpain
- —UnverifiedNorway
- —UnverifiedRomania
- —UnverifiedNetherlands
- —UnverifiedBelgium
- —UnverifiedFrance
- —UnverifiedGreece
- —UnverifiedGermany
- —UnverifiedCzechia
- —UnverifiedDenmark
Common questions
What does 'MSI-H' or 'dMMR' mean?
These are genetic terms that describe specific changes in your cancer cells. They are important because they can help doctors decide which treatments might work best for you.
What is an 'infusion'?
An infusion means the medicine is given slowly into your body through a vein, usually in your arm, using a drip.
What is immunotherapy?
Immunotherapy is a type of treatment that uses your body's own immune system to fight cancer cells.
Will I know which treatment I am getting?
In this study, treatments are assigned randomly, and often you and your doctors might not know which specific treatment you are receiving until the study concludes. This helps make the study results as fair as possible.
How long does the study last?
The length of time you'll be on treatment will depend on how you respond and whether the treatment is still helping. There will also be a follow-up period after treatment finishes.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.